Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company at the forefront of advancing cell therapies for cancer and autoimmune diseases. Utilizing adult stem cells, specifically induced pluripotent stem cells (iPSCs), Century Therapeutics leverages its proprietary Allo-Evasion™ technology to develop curative therapies that overcome the limitations of first-generation cell therapies.
The company's innovative platform integrates several advanced technologies including CRISPR-mediated gene editing, proprietary chimeric antigen receptors (CARs), and cutting-edge manufacturing capabilities. These combined elements enhance cell product performance, prevent host immune system rejection, and minimize development risks, positioning Century Therapeutics as a leader in the biotech sector.
Key Candidates and Achievements
- CNTY-101: An investigational CD19-targeting iPSC-derived natural killer (NK) cell therapy, CNTY-101 is designed for treating relapsed or refractory non-Hodgkin lymphoma (NHL). This product incorporates six precision gene edits and has shown promising early response signals, including complete and partial responses in clinical trials.
- Allo-Evasion™ Technology: Core to Century's strategy, this technology enables repeat dosing without the need for continual lymphodepletion, significantly improving patient outcomes. The company presented comprehensive data demonstrating the protective capabilities of its Allo-Evasion™ edits at major scientific conferences.
- Dual-Targeting CARs: Century has developed a novel CD19xCD22 bispecific CAR, demonstrating effective cytotoxicity against tumors in preclinical models, further expanding the potential applications of its therapies.
Recent News and Developments
- Clinical Trial Success: The ELiPSE-1 Phase 1 trial showcased encouraging initial data for CNTY-101, revealing its potential in treating aggressive B-cell lymphomas.
- New Partnerships and Acquisitions: The acquisition of Clade Therapeutics, a leader in iPSC-derived αβ T cells, enhances Century's pipeline, technology, and expertise in the cell therapy space.
- Financial Growth: Century recently secured $60 million in private placement funding, underscoring investor confidence in its strategic direction and potential market impact.
- Research Expansion: The company is expanding its clinical development into autoimmune disease indications, with a focus on leveraging its iPSC platform to address significant unmet medical needs.
For more detailed information about Century Therapeutics and its groundbreaking work in cell therapy, visit www.centurytx.com.
Century Therapeutics (NASDAQ: IPSC) announced preclinical data from its iPSC-based cell therapy platform will be presented at the AACR Annual Meeting on April 17, 2023. The poster, titled 'iPSC-derived CAR-NK cell therapy: nominating clinical candidate clones through integrated multi-functional analysis', features abstract number 2914 and will be presented by Michael Hall, PhD from the company. This clinical-stage biotechnology firm focuses on developing innovative cell therapies to target cancer, leveraging adult stem cells to provide improved treatment options and broader patient access. For more details, visit Century Therapeutics.
Century Therapeutics (NASDAQ: IPSC), a clinical-stage biotechnology firm, announced participation in two key investor conferences. The H.C. Wainwright Cell Therapy Virtual Conference will feature a fireside chat on February 28, 2023, at 10:30 AM ET. Additionally, the Cowen 43rd Annual Health Care Conference presentation is set for March 6, 2023, at 11:10 AM ET. Replays of both events will be accessible for 30 days via the company's website's “Events & Presentations” section. Century Therapeutics focuses on developing induced pluripotent stem cell-derived therapies to improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) has announced that the first patient has been dosed in the Phase 1 ELiPSE-1 trial of CNTY-101, a novel allogeneic cell therapy targeting relapsed or refractory CD19-positive B-cell lymphomas. This investigational therapy incorporates six precision gene edits, including a CD19 CAR and Allo-Evasion™ technology, designed to overcome immune rejection. The trial aims to assess CNTY-101's safety, tolerability, and preliminary efficacy through a unique multi-dosing strategy, potentially paving the way for innovative cell therapy treatments.
On February 1, 2023, Century Therapeutics (NASDAQ: IPSC) announced its participation in two upcoming investor conferences. The first event, The Guggenheim Healthcare Talks Oncology Day, is scheduled for February 8, 2023, at 3:55 PM ET. The second, The SVB Securities Global Biopharma Conference, will take place on February 15, 2023, at 11:20 AM ET. A replay of these events will be available on the company’s website for 30 days following the conferences. Century Therapeutics is focused on developing iPSC-derived cell therapies for cancer treatment, aiming to improve patient access and outcomes in oncology.
Century Therapeutics (NASDAQ: IPSC) has announced a strategic portfolio prioritization aimed at extending its cash runway into 2026. The company will focus on CNTY-101 for relapsed/refractory B-cell lymphoma and CNTY-107 for Nectin-4+ tumors, while de-prioritizing CNTY-103 for glioblastoma. A workforce reduction of approximately 25% has been implemented to support this strategy. The Phase 1 study of CNTY-101 remains on track, with no impact on the partnered programs with Bristol Myers Squibb. CEO Lalo Flores emphasizes the importance of these changes for achieving key development milestones.
Century Therapeutics (NASDAQ: IPSC) will have its CEO, Lalo Flores, present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 9:45 AM PT. As a biotechnology company specializing in iPSC-derived cell therapies for cancer treatment, Century aims to address the limitations of traditional therapies. A live webcast of the presentation will be available on their website, with a replay accessible for a limited time. For more company insights, visit Century Therapeutics.
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will engage in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 2:00 PM ET. A live webcast of the event will be accessible on the company's website, with an archived replay available for a limited time. The company focuses on developing iPSC-derived cell therapies to address cancer, leveraging advanced cellular reprogramming and genetic engineering. Their goal is to create off-the-shelf cell therapies that enhance patient access and improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) announced significant preclinical advancements in its iPSC-derived cell therapy platform, showcased at the SITC 37th Annual Meeting. Key highlights include effective anti-tumor activity of iPSC-derived CAR gamma delta T cells and the nomination of CNTY-107, targeting Nectin-4 for solid tumors, with an IND filing expected in 2025. The company is enhancing its iNK cell platform, focusing on genetic modifications for improved efficacy and safety. Century is set to provide further insights during a virtual R&D Day on November 11, 2022.
Century Therapeutics (NASDAQ: IPSC) reported its third-quarter 2022 results, revealing a cash position of $395.3 million and a net loss of $30.7 million. The company expects to initiate the Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory CD19 positive B-cell malignancies soon. R&D expenses increased to $25.9 million, primarily due to higher personnel costs. Century has reduced its GAAP operating expenses guidance for 2022 to $140 million to $145 million, and forecasts a cash runway into 2025.
Century Therapeutics (NASDAQ: IPSC) will host a virtual Research and Development Day on November 11, 2022, from 8:00 AM to 9:30 AM ET. This event will feature presentations from the management team and Dr. Jonathan Rosenberg from Memorial Sloan Kettering Cancer Center, focused on the company's solid tumor strategy and gamma delta iT cell platform. Preclinical data will also be presented at the Society for Immunotherapy of Cancer's 37th Annual Meeting. More details can be found on the company's website under Events & Presentations.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
What is Century Therapeutics' primary focus?
What is CNTY-101?
How does Century Therapeutics' Allo-Evasion™ technology work?
What recent achievements has Century Therapeutics made?
What are the potential applications of Century's dual-targeting CARs?
What are Century Therapeutics' plans for autoimmune diseases?
How does Century Therapeutics ensure the safety of its cell therapies?
What financial milestones has Century Therapeutics recently achieved?
Where can I find more information about Century Therapeutics?
What partnerships does Century Therapeutics have?
